Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Tango Therapeutics (TNGX) over the last 5 years, with Q3 2025 value amounting to 0.54%.

  • Tango Therapeutics' Return on Capital Employed fell 1100.0% to 0.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.54%, marking a year-over-year decrease of 1100.0%. This contributed to the annual value of 0.45% for FY2024, which is 1500.0% down from last year.
  • Tango Therapeutics' Return on Capital Employed amounted to 0.54% in Q3 2025, which was down 1100.0% from 0.73% recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Return on Capital Employed peaked at 0.12% during Q3 2021, and registered a low of 0.73% during Q2 2025.
  • Over the past 5 years, Tango Therapeutics' median Return on Capital Employed value was 0.31% (recorded in 2023), while the average stood at 0.33%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first skyrocketed by 500bps in 2022, then plummeted by -3500bps in 2025.
  • Over the past 5 years, Tango Therapeutics' Return on Capital Employed (Quarter) stood at 0.12% in 2021, then tumbled by -129bps to 0.28% in 2022, then fell by -10bps to 0.31% in 2023, then crashed by -59bps to 0.49% in 2024, then dropped by -9bps to 0.54% in 2025.
  • Its Return on Capital Employed stands at 0.54% for Q3 2025, versus 0.73% for Q2 2025 and 0.56% for Q1 2025.